46 related articles for article (PubMed ID: 31515667)
1. Effect of food and polymorphisms in SLCO2B1, CYP3A4 and UGT1A4 on pharmacokinetics of abiraterone and its metabolites in Chinese volunteers.
Hu Y; Wu J; Cheng B; You R; Yin X; Chen G; Yang L; Zhang Y; Si L; Jiang H; Zhang Y; Huang J; Huang J
Br J Clin Pharmacol; 2024 Jan; 90(1):247-263. PubMed ID: 37574850
[TBL] [Abstract][Full Text] [Related]
2. Bioavailability Enhancement and Food Effect Elimination of Abiraterone Acetate by Encapsulation in Surfactant-Enriched Oil Marbles.
Boleslavská T; Rychecký O; Krov M; Žvátora P; Dammer O; Beránek J; Kozlík P; Křížek T; Hořínková J; Ryšánek P; Roušarová J; Canová NK; Šíma M; Slanař O; Štěpánek F
AAPS J; 2020 Sep; 22(6):122. PubMed ID: 32978690
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of new formulation concepts for abiraterone acetate bioavailability enhancement based on the inhibition of pH-induced precipitation.
Boleslavská T; Světlík S; Žvátora P; Bosák J; Dammer O; Beránek J; Kozlík P; Křížek T; Kutinová Canová N; Šíma M; Slanař O; Štěpánek F
Eur J Pharm Biopharm; 2020 Jun; 151():81-90. PubMed ID: 32298757
[TBL] [Abstract][Full Text] [Related]
4. Concomitant intake of abiraterone acetate and food to increase pharmacokinetic exposure: real life data from a therapeutic drug monitoring programme.
Groenland SL; van Nuland M; Bergman AM; de Feijter JM; Dezentje VO; Rosing H; Beijnen JH; Huitema ADR; Steeghs N;
Eur J Cancer; 2020 May; 130():32-38. PubMed ID: 32172196
[TBL] [Abstract][Full Text] [Related]
5. Adjusting Overall Survival Estimates for Treatment Switching in Metastatic, Castration-Sensitive Prostate Cancer: Results from the LATITUDE Study.
Feyerabend S; Saad F; Perualila NJ; Van Sanden S; Diels J; Ito T; De Porre P; Fizazi K
Target Oncol; 2019 Dec; 14(6):681-688. PubMed ID: 31754962
[TBL] [Abstract][Full Text] [Related]
6. Functional impact of androgen-targeted therapy on patients with castration-resistant prostate cancer.
Beer TM; Shore N; Morgans A; Winters-Stone K; Wefel JS; George DJ
BJUI Compass; 2022 Nov; 3(6):424-433. PubMed ID: 36267196
[TBL] [Abstract][Full Text] [Related]
7. The effect of chemotherapy on the exposure-response relation of abiraterone in metastatic castration-resistant prostate cancer.
Boerrigter E; Benoist GE; Overbeek JK; Donders R; Mehra N; van Oort IM; Ter Heine R; van Erp NP
Br J Clin Pharmacol; 2022 Mar; 88(3):1170-1178. PubMed ID: 34436788
[TBL] [Abstract][Full Text] [Related]
8. Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE).
Saad F; Chi KN; Shore ND; Graff JN; Posadas EM; Lattouf JB; Espina BM; Zhu E; Yu A; Hazra A; De Meulder M; Mamidi RNVS; Bradic B; Francis P; Hayreh V; Rezazadeh Kalebasty A
Cancer Chemother Pharmacol; 2021 Jul; 88(1):25-37. PubMed ID: 33754187
[TBL] [Abstract][Full Text] [Related]
9. AR-V7 as a Biomarker for Resistance to Treatment with Abiraterone/Enzalutamide in Three Latin American Countries: A Hypothetical Cost-Saving Analysis.
Pacheco-Orozco RA; Montealegre-Páez L; Cayol F; Martínez-Gregorio H; Oliver J; Frecha C; Vaca-Paniagua F; Perdomo S
Oncologist; 2020 Dec; 25(12):e1990-e1995. PubMed ID: 32721059
[TBL] [Abstract][Full Text] [Related]
10. Demonstrating Bioequivalence for Two Dose Strengths of Niraparib and Abiraterone Acetate Dual-Action Tablets Versus Single Agents: Utility of Clinical Study Data Supplemented with Modeling and Simulation.
Yu A; Hazra A; Jiao JJ; Hellemans P; Mitselos A; Tian H; Ruixo JJP; Haddish-Berhane N; Ouellet D; Russu A
Clin Pharmacokinet; 2024 Apr; 63(4):511-527. PubMed ID: 38436924
[TBL] [Abstract][Full Text] [Related]
11. Bioequivalence, food effect and comparative pharmacokinetics of SUVN-1105, a novel granule formulation of abiraterone acetate, to Zytiga in healthy male subjects.
Nirogi R; Ravula J; Benade V; Goyal VK; Pandey SK; Dogiparti D; Jayarajan P; Kalaikadhiban I; Jetta S; Palacharla VRC
Cancer Chemother Pharmacol; 2024 Mar; 93(3):253-264. PubMed ID: 38157042
[TBL] [Abstract][Full Text] [Related]
12. Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer.
Chi KN; Spratlin J; Kollmannsberger C; North S; Pankras C; Gonzalez M; Bernard A; Stieltjes H; Peng L; Jiao J; Acharya M; Kheoh T; Griffin TW; Yu MK; Chien C; Tran NP
J Clin Pharmacol; 2015 Dec; 55(12):1406-14. PubMed ID: 26096139
[TBL] [Abstract][Full Text] [Related]
13. Oral formulation strategies to improve the bioavailability and mitigate the food effect of abiraterone acetate.
Schultz HB; Meola TR; Thomas N; Prestidge CA
Int J Pharm; 2020 Mar; 577():119069. PubMed ID: 31981706
[TBL] [Abstract][Full Text] [Related]
14. Fed or fasted state for oral therapies in breast cancer treatment? A comprehensive review of clinical practice recommendations.
Nicolò E; Trapani D; Berton Giachetti PPM; Zagami P; Curigliano G
Cancer Treat Rev; 2021 Nov; 100():102281. PubMed ID: 34500366
[TBL] [Abstract][Full Text] [Related]
15. A prospective phase I multicentre randomized cross-over pharmacokinetic study to determine the effect of food on abiraterone pharmacokinetics.
Lubberman FJE; Benoist GE; Gerritsen W; Burger DM; Mehra N; Hamberg P; van Oort I; van Erp NP
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1179-1185. PubMed ID: 31515667
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
